Literature DB >> 12583455

Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework.

N Mounier1, C Ferme, H Flechtner, M Henzy-Amar, E Lepage.   

Abstract

BACKGROUND: The standard Q-TWiST approach defines a series of health states and weights each state's duration according to its quality of life (QOL) to calculate quality-adjusted lifetimes. However, a fixed weight may not adequately reflect time variations in QOL.
METHODS: To account for measurements derived from irregular visits and informative missing data, the authors estimated the mean QOL profile using a mixed-effect growth curve model for the response, combined with a logistic regression model for the drop-out process.
RESULTS: Using data from a clinical study of lymphoma patients, the authors demonstrated better readaptation to normal life for patients younger than 30. Sensitivity analyses and computer simulations demonstrated that modeling the drop-out probability as a function of the QOL measurements is necessary if conditioning by health state is not possible.
CONCLUSION: Our model-based approach is useful to analyze studies with incomplete QOL data, especially when approximate QOL assessment by health state is not possible.

Entities:  

Mesh:

Year:  2003        PMID: 12583455     DOI: 10.1177/0272989X02239650

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  2 in total

1.  Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.

Authors:  Davide Radice; Alberto Redaelli
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Calibration of quality-adjusted life years for oncology clinical trials.

Authors:  Jeff A Sloan; Daniel J Sargent; Paul J Novotny; Paul A Decker; Randolph S Marks; Heidi Nelson
Journal:  J Pain Symptom Manage       Date:  2013-11-15       Impact factor: 3.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.